title: Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
authors.forename: Nicholas M
authors.initials: NM
authors.lastname: Dello Russo
authors.forename: Marjorie K
authors.initials: MK
authors.lastname: Jeffcoat
authors.forename: Robert E
authors.initials: RE
authors.lastname: Marx
authors.forename: Paul
authors.initials: P
authors.lastname: Fugazzotto
mesh_terms: D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010010:Osteoclasts / Q000187:drug effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy*; D010455:Peptides / Q000097:blood; D012449:Safety
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide